On Friday, Ginkgo Bioworks Holdings Inc (NYSE: DNA) opened higher 8.71% from the last session, before settling in for the closing price of $13.55. Price fluctuations for DNA have ranged from $5.26 to $64.40 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 104.75%. Company’s average yearly earnings per share was noted 45.22% at the time writing. With a float of $36.49 million, this company’s outstanding shares have now reached $41.37 million.
Let’s determine the extent of company efficiency that accounts for 1218 employees. In terms of profitability, gross margin is 63.73%, operating margin of -271.32%, and the pretax margin is -298.94%.
Ginkgo Bioworks Holdings Inc (DNA) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Ginkgo Bioworks Holdings Inc is 33.02%, while institutional ownership is 58.57%. The most recent insider transaction that took place on Feb 14 ’25, was worth 1,386. Before that another transaction happened on Feb 13 ’25, when Company’s Officer proposed sale 99 for $12.68, making the entire transaction worth $1,255.
Ginkgo Bioworks Holdings Inc (DNA) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 45.22% per share during the next fiscal year.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Trading Performance Indicators
Check out the current performance indicators for Ginkgo Bioworks Holdings Inc (DNA). In the past quarter, the stock posted a quick ratio of 5.79. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.68.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -12.90, a number that is poised to hit -1.50 in the next quarter and is forecasted to reach -5.81 in one year’s time.
Technical Analysis of Ginkgo Bioworks Holdings Inc (DNA)
Looking closely at Ginkgo Bioworks Holdings Inc (NYSE: DNA), its last 5-days average volume was 1.93 million, which is a jump from its year-to-date volume of 1.61 million. As of the previous 9 days, the stock’s Stochastic %D was 41.19%. Additionally, its Average True Range was 1.62.
During the past 100 days, Ginkgo Bioworks Holdings Inc’s (DNA) raw stochastic average was set at 80.44%, which indicates a significant increase from 62.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 138.50% in the past 14 days, which was higher than the 107.63% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.27, while its 200-day Moving Average is $13.06. However, in the short run, Ginkgo Bioworks Holdings Inc’s stock first resistance to watch stands at $15.40. Second resistance stands at $16.07. The third major resistance level sits at $16.81. If the price goes on to break the first support level at $13.99, it is likely to go to the next support level at $13.25. Now, if the price goes above the second support level, the third support stands at $12.58.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Key Stats
There are currently 57,479K shares outstanding in the company with a market cap of 802.49 million. Presently, the company’s annual sales total 251,460 K according to its annual income of -892,870 K. Last quarter, the company’s sales amounted to 89,050 K and its income totaled -56,400 K.
